


# EUROTHROMBOSIS

summit

**2012** October 11<sup>th</sup> - 13<sup>th</sup>  
Vienna, Austria



## Update on Thrombosis

Meeting of the Working Group on Thrombosis  
European Society of Cardiology

## Final Program

**Thrombosis**

ESC Working Group



EUROPEAN  
SOCIETY OF  
CARDIOLOGY®

# EUROTHROMBOSIS 2012

October 11<sup>th</sup> - 13<sup>th</sup>  
Vienna, Austria



## Main Topics

Acute Coronary Syndromes  
Antiplatelet Agents  
Anticoagulants  
Atrial Fibrillation  
Basic Research  
Bleeding  
Cerebrovascular Disease  
Coronary Thrombosis  
Diabetes  
Inflammation and Thrombosis  
Metabolic Syndrome  
Platelet Reactivity  
Platelet Function Testing  
Proteomics/Lipidomics/Metabolomics  
Stroke

<http://www.eurothrombosis-summit2012.org>

## Preface

The **EuroThrombosis Summit 2012** meeting is the annual scientific meeting of the **Working Group on Thrombosis of the European Society of Cardiology (ESC)**. The **EuroThrombosis Summit** meeting has a strong interest in clinical research, which takes about 80% of its contents, but there is always a small basic research part present. The meeting has been held for the last time in Oporto 2011. Based on the recent developments and upgrades of international guidelines with respect to antithrombotic therapy in cardiovascular diseases, it has been decided to organize the **EuroThrombosis Summit** again in **2012 in Vienna, Austria**, which will then be followed in 2013 by the translational research related **EuroThrombosis 2013** meeting in **Uppsala, Sweden (October 3-5, 2013)**.

As organizers we were extremely interested to include the newest guidelines and clinical developments into this meeting. But we also want to inform a highly motivated and interested audience about new developments in basic research with potential implication for the future. We were successful in the invitation of outspoken international experts in the field who will make the event an unforgettable experience. As a new strategy in planning in the meeting organization and to give young scientists an audience they deserve but rarely have seen in the past, we had to merge clinical symposia with clinical and basic research (translational medicine) by inviting one or two best rated abstracts into some of the pre-defined symposia. In opposite to the meetings of the past parallel sessions have been kept to a minimum.

We are grateful to the industry for sponsoring the **EuroThrombosis Summit 2012** again by organizing and financing satellite/special symposia and taking part in the medical exhibition.

We are convinced that the **EuroThrombosis Summit 2012** will become a milestone of antithrombotic treatment in cardiovascular diseases and of clinical and basic (translational) thrombosis research.



Kurt Huber



Johann Wojta

Vienna, September 2012

## Organizers

Kurt Huber (Austria) – clinical research  
Johann Wojta (Austria) – basic research



## Congress Secretaries

Stefan Kastl (Austria) – basic research  
Thomas Weiss (Austria) – clinical research



Thrombosis

ESC Working Group

EUROPEAN  
SOCIETY OF  
CARDIOLOGY

## Scientific Board

Felicita Andreotti (Italy)  
Lina Badimon (Spain)  
Marco Cattaneo (Italy)  
Jean-Philippe Collet (France)  
Raffaele De Caterina (Italy)  
Dietrich Gulba (Germany)  
Steen Husted (Denmark)  
Gregory Lip (United Kingdom)

João Morais (Portugal)  
Franz-Josef Neumann (Germany)  
Lars Rasmussen (Denmark)  
Karsten Schrör (Germany)  
Agneta Siegbahn (Sweden)  
Jolanta Siller-Matula (Austria)  
Robert Storey (United Kingdom)  
Freek Verheugt (The Netherlands)

## Invited Faculty

Harald Arnesen (Norway)  
Dan Atar (Norway)  
Lina Badimon (Spain)  
Johann Bauersachs (Germany)  
Christoph Binder (Austria)  
Marco Cattaneo (Italy)  
Peter Clemmensen (Denmark)  
Jean-Philippe Collet (France)  
Harald Darius (Germany)  
Sabine Eichinger-Hasenauer (Austria)  
Peter Grant (United Kingdom)  
Erik Grove (Denmark)  
Dietrich Gulba (Germany)  
Sigrun Halvorsen (Norway)  
Katherina Heß (Germany)  
Kurt Huber (Austria)  
Stefan Kastl (Austria)  
Robert Gabor Kiss (Hungary)  
Wolfgang Koenig (Germany)  
Elisabeth Mahla (Austria)  
Manuel Mayr (United Kingdom)

João Morais (Portugal)  
Andrew Newby (United Kingdom)  
Alexander Niessner (Austria)  
Franz-Josef Neumann (Germany)  
Lars Rasmussen (Denmark)  
Karsten Schrör (Germany)  
Helmut Schühlen (Germany)  
Ingebjorg Seljeflot (Norway)  
Victor Serebruany (USA)  
Dirk Sibbing (Germany)  
Agneta Siegbahn (Sweden)  
Jolanta Siller-Matula (Austria)  
Walter Speidl (Austria)  
Miguel Sousa Uva (Portugal)  
Robert Storey (United Kingdom)  
Dietmar Trenk (Germany)  
Marco Tubaro (Italy)  
Freek W.A. Verheugt (The Netherlands)  
Christian Weber (Germany)  
Thomas Weiss (Austria)  
Johann Wojta (Austria)

## Thursday, October 11, 2012

<b>10:30-12:00</b>	<b>Symposium 1: Atrial Fibrillation</b>	<b>Main hall</b>
	Chairs: Kurt Huber, AT; Robert G. Kiss, HU	
10:30-10:55	<ul style="list-style-type: none"><li>Coagulation markers in atrial fibrillation – predictors of stroke and bleeding Agneta Siegbahn, SE</li></ul>	
10:55-11:20	<ul style="list-style-type: none"><li>New oral anticoagulants in atrial fibrillation: Unanswered questions and practical issues Kurt Huber, AT</li></ul>	
11:20-11:45	<ul style="list-style-type: none"><li>Triple therapy Freek W.A. Verheugt, NL</li></ul>	
11:45-12:00	<ul style="list-style-type: none"><li>Safety and efficacy new oral anticoagulants compared to warfarin in patients with atrial fibrillation: Systematic review and Bayesian network meta-analysis focusing on subgroup results for age, time in therapeutic range and CHADS2 score Sabine Steiner, AT</li></ul>	

<b>12:00-13:00</b>	<b>Special/Satellite Symposium I</b> <b>(sponsored by BOEHRINGER-INGELHEIM):</b> <b>Stroke Prevention in Atrial Fibrillation:</b> <b>New Approaches and Practical Guidelines</b>	<b>Main hall</b>
	Chair: Kurt Huber, AT	
12:00-12:17	<ul style="list-style-type: none"><li>This is why we need to advance: New 2012 ESC Atrial Fibrillation Guidelines Lars Rasmussen, DK</li></ul>	
12:17-12:34	<ul style="list-style-type: none"><li>Mapping a changing landscape: Translating RE-LY into clinical practice Jonas Oldgren, SE</li></ul>	
12:34-12:51	<ul style="list-style-type: none"><li>Let experience be our guide: using a new oral anticoagulant in everyday clinical practice Kurt Huber, AT</li></ul>	
12:51-13:00	<ul style="list-style-type: none"><li>Q &amp; A (Panel Discussion)</li></ul>	

## Thursday, October 11, 2012

- 12:00-13:00**      **Special/Satellite Symposium II**      **Reitersaal**  
*(sponsored by TERUMO/The Medicines Company):*  
**AMI-Treatment – Chain of Success**
- Chairs: Michael Hirschl, AT; Stefan Hoffmann, DE
- 12:00-12:15      • STEMI: radial access state of the art – essential medical therapy  
Stefan Hoffmann, DE
- 12:15-12:30      • Anticoagulation and the cellular model of hemostasis  
Christian Hengstenberg, DE
- 12:30-12:45      • Thrombus aspiration – in all myocardial infarction patients?  
Guy Friedrich, AT
- 12:45-13:00      • Seeing is understanding – OCT new imaging technique  
Christopher Wolf, AT
- 13:00-13:45      *Lunch Break, Exhibition*
- 13:45-14:00**      **Opening Ceremony**      **Main hall**
- 14:00-15:30**      **Symposium 2: Monocytes, Macrophages, B-cells, T-cells in Atherosclerosis – Subsets, Subsets, Subsets: Can We Still See the Forest for the Trees?**      **Main hall**
- Chairs: Katherina Heß, DE; Lina Badimon, ES
- Monocytes subsets in the pathogenesis of atherosclerosis. Lessons from mice and men.  
Christian Weber, DE
  - Macrophage heterogeneity in atherosclerotic lesions.  
Andrew Newby, UK
  - B-cells and antibodies in atherosclerosis.  
Christoph Binder, AT
  - T-cell subsets and adaptive immunity in atherosclerosis.  
Alexander Niessner, AT

## Thursday, October 11, 2012

**14:00-15:00**      **Special/Satellite Symposium III**      **Reitersaal**  
*(sponsored by BRISTOL-MYERS SQUIBB/PFIZER):*

**Stroke Prevention in Atrial Fibrillation:  
New Guidelines and New Therapeutic Options**

Chair: Kurt Huber, AT

- 14:00-14:17      • Recommendations and Guidelines for Stroke Prevention in Atrial Fibrillation  
Dan Atar, NO
- 14:17-14:34      • New therapeutic approaches for Stroke Prevention in Atrial Fibrillation  
Kurt Huber, AT
- 14:34-14:51      • Post-stroke management of patients with atrial fibrillation  
Peter Kelly, IE
- 14:51-15:00      • Q & A (Panel Discussion)

*15:00-16:00*      *Coffee Break, Exhibiton*

**16:00-18:00**      **Symposium 3: Important Clinical Aspects in**      **Main hall**  
**Antithrombotic Therapy**

Chairs: Lars Rasmussen, DK; Robert Storey UK

- 16:00-16:20      • Assays for new anticoagulants  
Sabine Eichinger-Hasenauer, AT
- 16:20-16:40      • How to manage bleeding or overdose  
Peter Clemmensen, DK
- 16:40-17:00      • Pre-operative strategies in patients referred for CABG  
Miguel Sousa Uva, PT
- 17:00-17:20      • Platelet function testing: Finding the optimal time for surgery  
Elisabeth Mahla, AT
- 17:20-17:40      • Optimizing P2Y12-recdeptor inhibition in acute coronary syndrome patients after PCI using platelet function testing: impact of prasugrel versus high-dose clopidogrel  
Daniel Aradi, HU
- 17:40-18:00      • Prognostic and diagnostic performance of platelet function testing: implications for clinical utility  
Jeffrey Dahlen, USA

**Thursday, October 11, 2012**

**18:00-19:00**

**Poster Discussion A/1 – Biomarker**

**Poster area, Foyer**

Moderator: Thomas Weiss, AT

- Plasma fibrinolytic activity in patients with recent-onset atrial fibrillation and structurally normal hearts  
A. Penev, M. Negreva, J. Nyagolov (Bulgaria)
- Fibrinogen in insulin dependent diabetics  
S. Pajovic, S. Lazic, D. Celic (Kosovo)
- The profile of circulating growth differentiation factor 15 after percutaneous coronary intervention in patients with acute myocardial or stable angina pectoris.  
S. Solheim, H. Arnesen, I. Seljeflot (Norway)
- The role of level of testosterone on coronary artery disease in men aged 40-50 years old  
L. Bica, M. Lezha (Albania)
- Coronary angiographic findings and pregnancy-associated plasma protein-A (PAPP-A) levels in patients presenting with acute coronary syndromes  
M. Shehata, A. Adel, M. Tawfek, A. Fathy (Egypt)
- Prognostic value of fibronectin fragmentation for thrombotic risk assessment in Q-wave myocardial infarction patients  
O. Koval, A. Ivanov (Ukraine)
- Determinants of platelet production in patients with coronary artery disease  
S.B. Larsen, A.-M. Hvas, S.D. Kristensen, E.L. Grove (Denmark)
- Relevance of Copeptin for Employment of Dual Biomarker Strategy in Diagnosis of ACS –WILCOP-Study.  
M. Tajsic, R. Jarai, J. Koch, M. Schwarz, J. Kitzbrecht, J. Wojta, and K. Huber (Austria)
- Copeptin as a Part of the Dual Biomarker Strategy for Early Diagnosis of NSTEMI – WILCOP-Study.  
M. Tajsic, R. Jarai, J. Koch, M. Schwarz, J. Kitzbrecht, J. Wojta, and K. Huber (Austria)

## Thursday, October 11, 2012

### 18:00-19:00      **Poster Discussion A/2 – Miscellaneous**      **Poster area, Foyer**

Moderator: Sigrun Halvorsen, NO

- Presence of spontaneous echo contrast is associated with CHA<sub>2</sub>DS<sub>2</sub>-VAsC score in patients with atrial fibrillation  
O. Uz, Z. Isilak, F. Kilicasian, M. Tezcan, M. Yalcin, M. Uzun, B.S. Cebeci (Turkey)
- Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation  
M. Freynhofer, S. Gruber, V. Bruno, T. Höchtl, S. Farhan, V. Zaller, J. Wojta, K. Huber (Austria)
- Adherence to guidelines for atrial fibrillation management in dysvascular lower limb amputee patients  
S. Ralevic, J. Perunicic, B. Vidakovic, J. Maksimovic, Z. Kovacevic, T. Blagojevic (Serbia)
- Predictors of venous thrombosis in patients with antiphospholipid syndrome  
I.M. Ion, A. Baicus, C. Baicus, S. Caraiola (Romania)
- Normal coronary arteries and myocardial infarction-case report  
S. Lazic, S. Pajovic, D. Celic, M. Sipic (Kosovo)
- Thrombectomy in the acute phase of cerebral ischemia with the Solitaire FR  
G. Mayrhofer, H. Wallner, W. Goebel, H. Lafenthaler, M. Schmidjel, E. Sandlhofer, I. Huemer, J. Westreicher, M. Huemer, N. Hondl, R. Lenzhofer (Austria)

20:00

*Faculty Dinner*

## Friday, October 12, 2012

### 08:30-10:00 **Symposium 4: Diabetes and Thrombosis** **Main hall**

Chairs: João Morais, PT; Victor Serebruany, US

- 08:30-08:55 • The epidemiology of cardiovascular disease in diabetes  
Wolfgang Koenig, DE
- 08:55-09:15 • The pathogenetic basis of increased thrombotic risk in diabetes  
Peter Grant, UK
- 09:15-09:40 • Response to antithrombotic agents in diabetes  
Marco Cattaneo, IT
- 09:40-10:00 • Diabetes: Challenge for interventional cardiology  
Helmut Schühlen, DE

10:00-10:30 *Break, Exhibiton*

### 10:30-12:30 **Symposium 5: High-on-treatment Platelet Reactivity** **Main hall**

***Joint Session with the Acute Cardiovascular Care Association (ACCA)***

Chairs: Peter Clemmensen, DK; Marco Cattaneo, IT

- 10:30-10:50 • HPR – Clinical background and definition  
Erik Grove, DK
- 10:50-11:15 • To measure platelet function: Facts or fiction  
Jean-Philippe Collet, FR
- 11:15-11:40 • Genetic profiling for patients under dual antiplatelet therapy: Already for clinical use?  
Dietmar Trenk, DE
- 11:40-12:05 • Clinical pharmacology of prasugrel and ticagrelor  
Karsten Schrör, DE
- 12:05-12:30 • Prasugrel and ticagrelor in high-risk ACS patients  
Marco Tubaro, IT

12:30-13:30 *Lunch Break*

## Friday, October 12, 2012

- 13:30-14:30**      **Special/Satellite Symposium IV**      **Main hall**  
*(sponsored by BAYER HEALTHCARE):*  
**Thrombosis Prevention: Describing the Present, Predicting the Future**
- Chairs: Kurt Huber, AT; Richard Hobbs, UK
- 13:30-13:47      • Anticoagulation in practice: is there room for improvement? An update from GARFIELD.  
Marianne Brodmann, AT
- 13:47-14:04      • The future of anticoagulation: what do the recent developments offer?  
Richard Hobbs, UK
- 14:04-14:21      • Secondary prevention in ACS: Potential future treatment options  
Joao Morais, PT
- 14:21-14:30      • Q & A (Panel Discussion)
- 13:30-14:30**      **Special/Satellite Symposium V**      **Reitersaal**  
*(sponsored by IROKO CARDIO INTERNATIONAL):*  
**Contemporary IV anti-platelet therapy in ACS-PCI Patients**
- Chair: Robert G. Kiss, HU
- 13:30-13:47      • Platelet blockade to real life: how, how fast, how deep?  
Karsten Schrör, DE
- 13:47-14:04      • Early platelet blockade in ACS: A benefit/risk ratio assessment  
Helmut Schühlen, DE
- 14:04-14:21      • Inhibiting platelet activity from guidelines to real life practice: Clinical cases  
Robert G. Kiss, HU
- 14:21-14:30      • Q & A (Panel Discussion)

## Friday, October 12, 2012

### 14:30-16:00 **Symposium 6: New Tools for New Tricks – -omics, Epigenetics, Micro RNAs and Microparticles in Cardiovascular Medicine** **Main hall**

Chairs: Johann Wojta, AT; Ingebjorg Seljeflot, NO

- 14:30-14:55
- Genomic fingerprinting and epigenetics. Ready for research cardiovascular medicine?  
Lina Badimon, ES
- 14:55-15:15
- Micro RNAs in cardiovascular disease.  
Johann Bauersachs, DE
- 15:15-15:35
- Microparticles: New techniques for measurement and biological meaning  
Agneša Siegbahn, SE
- 15:35-16:00
- From proteomics to lipidomics and metabolomics in cardiovascular research.  
Manuel Mayr, UK

### 14:30-16:00 **Best Abstracts A – oral presentations** **Reitersaal**

Chairs: Sigrun Halvorsen, NO; Rob Storey, UK

- 14:30-14:45
- Platelet function testing for investigating bleeding – the GAPP approach  
M. Lordkipanidze, G.C. Lowe, B.B. Dawood, D. Bem, M. Makris, A. Mumford, J. Wilde, S.P. Watson, M.E. Daly (United Kingdom)
- 14:45-15:00
- A novel method for rapid point-of-care determination of P2Y12 inhibition prior to percutaneous coronary intervention  
W. Sumaya, R.L. Daly, S. Mehra, A.J. Dhutia, K.E. Howgege, A.C. Morton, R.F. Storey (United Kingdom)
- 15:00-15:15
- Mean platelet volume variability in patients presenting with chest pain  
C. Delcea (Romania), D.E. Amariei (USA), A.C. Nechita, V. Enache, A.M. Andronescu, R.L. Ploesteanu, A.M. Stroi, S.C. Stamate, M.M. Vintila (Romania)

## Friday, October 12, 2012

<b>14:30-16:00</b>	<b>Best Abstracts A – oral presentations</b>	<b>Reitersaal</b>
15:15-15:30	<ul style="list-style-type: none"><li>Decreased interleukin-33 serum levels after coronary stent implantation are protective against in-stent restenosis S. Demyanets, R. Jarai, K.M. Katsaros, S. Farhan, A. Wonnerth, Th. Weiss, G. Maurer, W. Speidl, J. Wojta, K. Huber (Austria)</li></ul>	
15:30-15:45	<ul style="list-style-type: none"><li>Circulating MRP 8/14 is associated with thromboxane-dependent activation in NSTEMI patients: Effect of aspirin treatment F. Santilli, L. Paloscia, M. Mascellanti, S. Pascale, M. Di Marco, G. Ciabattoni, E. Ferrante, R. Liani, G. Davi (Italy)</li></ul>	
15:45-16:00	<ul style="list-style-type: none"><li>Evidence for pleiotropic of dabigatran involving factor Xla inhibition C. Klufft, K. van Leuven, J. Burggraaf (The Netherlands)</li></ul>	
16:00-16:30	<i>Break, Exhibition</i>	
<b>16:30-18:00</b>	<b>Symposium 7: Important Topics in Coagulation</b>	<b>Main hall</b>
	Chairs: Jean-Philippe Collet, FR; Harald Arnesen, NO	
16:30-16:55	<ul style="list-style-type: none"><li>The coagulation cascade: New concept Dietrich Gulba, DE</li></ul>	
16:55-17:20	<ul style="list-style-type: none"><li>Factor XIII: Mechanisms of action and clinical importance Peter Grant, UK</li></ul>	
17:20-17:40	<ul style="list-style-type: none"><li>Coagulation and the immune system Walter Speidl, AT</li></ul>	
17:40-18:00	<ul style="list-style-type: none"><li>Non-coagulatory effects of thrombin Karsten Schrör, DE</li></ul>	

**Friday, October 12, 2012**

**18:00-19:00 Poster Discussion B/1 – PCI**

**Poster area**

Moderation: Peter Clemmensen, DK

- Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis  
D. Aradi, A. Komócsi, M. Price, T. Cuisset, H. Ari, D. Hazarbasanov, D. Trenk, D. Sibing, M. Valgimigli, L. Bonello (Hungary, France, Bulgaria, Germany, Italy)
- Preliminary experience of a national outpatient stent thrombosis clinic to achieve tailor-made antiplatelet therapy in stent thrombosis patients  
T. Godschalk, H. Goossens, D. van Kessel, C. Hackeng, J. ten Berg (The Netherlands)
- Stent thrombosis and fibrinolytic therapy – a reasonable option?  
A. Baptista, C. Ferreira, P. Magalães, P. Mateus, A. Ferreira, H. Carvalho, I. Moreira (Portugal)
- The impact of bivalirudin and other peri-interventional anticoagulant strategies on clinical outcome in patients undergoing coronary stenting  
M. Rohla, I. Tentzeris, R. Jarai, M. Freynhofer, S. Farhan, J. Wojta and K. Huber (Austria)
- Novel approach of managing urgent bleeding in haemostasis in post cath-lab patient, using the old substances-case report  
D. Sarenac, B. Calija (Serbia)
- Conventional and novel risk factor specificities in younger and patients with myocardial infarction  
N. Antonijevic, L.J. Jovanovic, B. Jakovljevic, A. Beletic, N. Radovanovic, J. Perunicic, S. Obradovic, J. Stojanovic, I. Zivkovic, D. Matic, Z. Vasiljevic (Serbia)
- Impact of anti-thrombotic therapy on early and long-term bleeding complication after TAVI  
K. Czerwinska Jelonkiewicz, A. Witkowski, M. Dabrowski, M. Banaszewski, E. Ksiezycka-Majczynska, Z. Chielak, K. Kusmierski, T. Hryniewiecki, M. Demkow, J. Stepinska (Poland)
- Personalized antiplatelet treatment after PCI: The MADONNA study  
J.M. Siller-Matula, M. Francesconi, C. Dechant, B. Jilma, G. Maurer, G. Delle-Karth, G. Gouya, K. Ruzicka, A. Poderzek-Schweighofer, G. Christ (Austria)

20:00

*Social Evening*

**Friday, October 12, 2012**

**18:00-19:00 Poster Discussion B/2 – Miscellaneous**

**Poster area**

Moderation: Stefan Kastl, AT

- Use of ticlopidine in patients with resistance to clopidogrel after percutaneous coronary intervention  
L.J. Jovanovic, N. Antonijevic, I. Zivkovic, B. Terzic, N. Radovanovic, J. Perunicic, N. Savic, T. Kocica (Serbia)
- Shear-induced platelet aggregation in aspirin-treated patients: Initial experience with the novel PlaCor® device  
M. Würtz, A.M. Hvas, S.D. Kristensen, E.L. Grove (Denmark)
- High platelet aggregability and increased inflammatory markers and oxidative stress in mitral stenosis patients predispose to left atrial thrombus formation  
S. Satheesh, R. Medha, P. Vinaykumar, M. Vengatesan, P.H. Ananthanarayanan, J. Balachander (India)
- Increased inflammatory markers in patients with reduced antiplatelet effect of aspirin  
S. Bøjet Larsen, A.M. Hvas, S.D. Kristensen, E.L. Grove (Denmark)
- Interleukin-33 stimulates production of GM-CSF and M-CSF by human endothelial cells  
E. Montanari, C. Kaun, C.E. Lemberger, R. de Martin, G. Maurer, K. Huber, J. Wojta, S. Demyanets (Austria)
- Platelet adhesion measurements using impedimetry – the effect of heparin on platelet function  
L. Polgar, L. Kohidai, E. Lajko, O. Lang, C.S. Olah, A. Pungor, B. Merkely, P. Soos (Hungary)
- Testing the robustness of the Rosendaal method for calculating Time in Therapeutic Range (TTR) in patients treated with warfarin  
A. Scowcroft, S. Lee, J. Mant (United Kingdom)

## Saturday, October 13, 2012

### 08:30-10:00 **Symposium 8: The Metabolic Syndrome** **Main hall**

Chairs: Lina Badimon, ES; Wolfgang Koenig, DE

- 08:30-08:55
  - Obesity, inflammation and thrombosis.  
Johann Wojta, AT
- 08:55-09:20
  - B-cells, T-cells and macrophages and their role in insulin resistance.  
Katherina Heß, DE
- 09:20-09:45
  - Markers of inflammation in patients with metabolic syndrome.  
Ingebjorg Seljeflot, NO
- 09:45-10:00
  - Rosuvastatin reduces platelet recruitment by inhibiting NADPH oxidase activation  
Pasquale Pignatelli, IT

10:00-10:30 *Break, Exhibiton*

### 10:30-12:30 **Symposium 9: Controversies in Modern Antiplatelet Strategies** **Main hall**

Chairs: Franz-Josef Neumann, DE; Dietrich Gulba, DE

- 10:30-11:30
  - Aggressive antiplatelet therapy benefits patients  
Pro: Dirk Sibbing, DE  
Con: Victor Serebruany, US
- 11:30-12:30
  - Thrombin receptor antagonists are the welcome addition to dual antiplatelet therapy  
Pro: Harald Darius, DE  
Con: Robert Storey, UK

12:30-13:30 *Lunch Break*

## Saturday, October 13, 2012

**13:30-14:30**      **Special/Satellite Symposium VI**      **Main hall**  
*(sponsored by DAIICHI SANKYO):*

### **Novel Oral Anticoagulants – What Do We Know, What Can We Expect**

Chair: Kurt Huber, AT

- 13:30-13:47      • Novel anticoagulants in CV disease – Current knowledge and future challenges  
Felicitia Andreotti, IT
- 13:47-14:04      • ENGAGE AF – TIMI 48 – What can the study add to our current knowledge?  
Harald Darius, DE
- 14:04-14:21      • Novel oral anticoagulants in venous thromboembolism – current and future evidence  
Peter Verhamme, Belgium
- 14:21-14:30      • Q & A (Panel Discussion)

**13:30-15:00**      **Best Abstracts B – oral presentations**      **Reitersaal**

Moderation: Dan Atar, NO, Jolanta Siller-Matula, AT

- 13:30-13:45      • POPular Risk Score for individualized antiplatelet therapy following elective PCI  
T. Godschalk, T.H. Bergmeijer, P. Janssen, T. Oirbans, S. Martina, V. Deneer, C. Hackeng, J. ten Berg (The Netherlands)
- 13:45-14:00      • Fractalkine (CX3CL1) after PCI in patients with acute myocardial infarction or stable angina pectoris  
I.U. Njerve, I. Seljeflot, H. Arnesen, S. Solheim (Norway)
- 14:00-14:15      • Success rate of different treatment strategies of prosthetic valve thrombosis  
A. Nagy, M. Lengyel, M. Dénes (Hungary)
- 14:15-14:30      • The impact of bivalirudin and other peri-interventional anticoagulant strategies on bleeding complications and prolongation of hospitalization in patients undergoing coronary stenting  
M. Rohla, I. Tentzeris, R. Jarai, M. Freynhofer, S. Farhan, J. Wojta and K. Huber (Austria)

## Saturday, October 13, 2012

<b>13:30-15:00</b>	<b>Best Abstracts B – oral presentations</b>	<b>Reitersaal</b>
14:30-14:45	<ul style="list-style-type: none"><li>Levosimendan exhibits anti-inflammatory effects on human cardiac myocytes and human umbilical vein endothelial cells in vitro K.A. Krychtiuk, L. Watzke, C. Kaun, S. Demyanets, S.P. Kastl, A. Zuckermann, G. Maurer, K. Huber, J. Wojta, W.S. Speidl (Austria)</li></ul>	
14:45-15:00	<ul style="list-style-type: none"><li>Clinical characteristics and outcomes of patients with very late thrombosis in coronary bare metal stents E. Fdez-Obanza, A. Salgado Barreira, V.A. Jimenez Diaz, J. Sepulveda Sepulveda, J. Ponce Bustillo, A. Ortiz Saez, G. Bastos Fernandez, A. De Miguel Castro, J.A. Baz Alonso, A. Iñiguez Romo (Spain)</li></ul>	
<b>14:30-16:00</b>	<b>Symposium 10: News in Antiplatelet Therapy</b>	<b>Main hall</b>
	Chairs: Lars Rasmussen, DK; Harald Arnesen, NO	
14:30-14:55	<ul style="list-style-type: none"><li>What is the correct duration of dual antiplatelet therapy Franz-Josef Neumann, DE</li></ul>	
14:55-15:20	<ul style="list-style-type: none"><li>New antiplatelet agents in clinical testing and on the horizon Harald Darius, DE</li></ul>	
15:20-15:35	<ul style="list-style-type: none"><li>In-hospital thrombocytopenia in acute coronary syndromes Andreja Sinkovic, SI</li></ul>	
15:35-16:00	<ul style="list-style-type: none"><li>Antiplatelet therapy: Updates in the ESC guidelines 2011/2012 João Morais, PT</li></ul>	
16:00	<i>Farewell, Departures</i>	

## Local Organisation

Kurt Huber, MD, FESC, FACC  
Director, 3<sup>rd</sup> Department of Medicine  
Cardiology & Emergency Medicine  
Wilhelminenhospital, Montleartstrasse 37  
A-1160 Vienna, Austria  
Phone: (+43/1) 49 150-2301  
Fax: (+43/1) 49 150-2309  
E-mail: kurt.huber@wienkav.at

Johann Wojta  
Head of Research  
Department of Internal Medicine II  
Medical University of Vienna  
Währinger Gürtel 18-20, A-1090 Vienna  
Phone: (+43/1) 40400 73500  
Fax: (+43/1) 40400 73586  
E-mail: johann.wojta@meduniwien.ac.at

## Scientific Secretariat

Congress and Study Concept GesmbH  
Widerhoferplatz 4/3/19, A-1090 Vienna, Austria  
Contact: Ms. Mag. Franziska Beckmann  
Phone: (+43/699) 115 16917  
E-mail: csconcept@chello.at

## Official PCO, Registration and Accommodation

Mondial Congress & Events  
Mondial GmbH & Co. KG  
Operngasse 20b, A-1040 Vienna, Austria  
Phone: (+43/1) 58804-0  
Fax: (+43/1) 58804-185  
eurothrombosis2012@mondial-congress.com

## Medical Exhibition and Advertising

Medizinische Ausstellungs- und Werbegesellschaft  
Freyung 6, A-1014 Vienna, Austria  
Contact: Ms. Sonja Chmella  
Phone: (+43/1) 536 63-32, Fax: (+43/1) 535 60 16  
E-mail: maw@media.co.at, www.maw.co.at

## Venue

Palais Ferstel, Strauchgasse 4  
A-1010 Vienna, Austria

## Congress Fee:

€ 400.- total meeting  
€ 220.- per day

(50% reduced fee for members of the Working Group on Thrombosis and the  
Acute Cardiac Care Association of the ESC)

Free entrance for physicians in education, abstract and poster presenters,  
medical students and nurses

<http://www.eurothrombosis-summit2012.org>

## Notes

## Notes

## Sponsors (with September 2012)



Science For A Better Life



Bristol-Myers Squibb



Boehringer  
Ingelheim



Daiichi-Sankyo



IROKO CARDIO  
INTERNATIONAL



MSD

SANOFI 



THE MEDICINES COMPANY®

<http://www.eurothrombosis-summit2012.org>

